ZypAdhera® (olanzapinpamoat): Underhållsdos

Further information on maintenance dose

Olanzapine LAI provides therapeutic levels of systemic olanzapine from the very first injection. However, approximately 3 months are needed to re-establish steady state.¹

During treatment, dose may subsequently be adjusted on the basis of individual clinical status. After clinical reassessment, dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks (Table 1).²

Table 1. Recommended dose scheme between oral olanzapine and olanzapine pamoate²

These doses of olanzapine LAI have been shown to sustain steady-state olanzapine concentrations over 2 to 4 weeks that correspond to those maintained by an oral dose of 10 to 20 mg olanzapine administered once daily.³

Some specific patient populations may require cautious dose escalation.¹ For full information please refer to the summary of product characteristics.

Pharmacokinetic background information

The half-life of olanzapine after olanzapine pamoate is 30 days compared to 30 hours following oral administration.²

During the initial three months of treatment with olanzapine pamoate, accumulation of olanzapine was observed but there was no additional accumulation during long-term use (12 months) in patients who were injected with up to 300 mg every two weeks.²

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

3. Mitchell M, Kothare P, Bergstrom R, et al. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther. 2013;35(12):1890-1908. http://dx.doi.org/10.1016/j.clinthera.2013.09.023

Glossary

LAI = long-acting injection = olanzapine-pamoate